Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06578637 · ClinicalTrials.gov registry record · NA
Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis
A NA study of Familial Adenomatous Polyposis and FAP, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06578637 is a NA study of Familial Adenomatous Polyposis and FAP that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 20 participants, below the 247-participant average among 10 other Familial Adenomatous Polyposis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06578637, a NA study of Familial Adenomatous Polyposis and FAP, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to evaluate the potential of BHB supplementation as a novel strategy to impede the development and progression of intestinal adenomas in individuals with FAP, thus potentially reducing the need for frequent upper endoscopies and colonoscopies and preventing the need for risk-reducing surgical intervention.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT R-1,3-Butanediol (10G-A)
- DIETARY_SUPPLEMENT R-1,3-Butanediol (20G-A)
- DIETARY_SUPPLEMENT R-1,3-Butanediol (30G-A)
- DIETARY_SUPPLEMENT R-1,3-Butanediol (30G-B)
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-20 |
| Est. Completion | 2027-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06578637
The ClinicalTrials.gov registry entry for NCT06578637 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 247-participant average among 10 other Familial Adenomatous Polyposis trials with a reported enrollment target (92% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Familial Adenomatous Polyposis appearing as the primary indexed condition, and to 4 interventions - of which R-1,3-Butanediol (10G-A) is the first listed.
NCT06578637 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06578637 about?
NCT06578637 is a clinical study titled "Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis". The aim of this study is to evaluate the potential of BHB supplementation as a novel strategy to impede the development and progression of intestinal adenomas in individuals with FAP, thus potentially reducing the need for frequent upper endoscopies and colonoscopies and preventing the need for risk...
What is the current status of trial NCT06578637?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-09-20. Estimated completion is 2027-10.
What conditions does trial NCT06578637 study?
This clinical trial studies the following conditions: Familial Adenomatous Polyposis, FAP.
What interventions are being tested in trial NCT06578637?
The interventions under investigation include: R-1,3-Butanediol (10G-A) (DIETARY_SUPPLEMENT), R-1,3-Butanediol (20G-A) (DIETARY_SUPPLEMENT), R-1,3-Butanediol (30G-A) (DIETARY_SUPPLEMENT), R-1,3-Butanediol (30G-B) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06578637?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06578637 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Familial Adenomatous Polyposis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)
RECRUITING · NA
-
CryoBalloon Ablation for Treatment of Duodenal Adenomas
ACTIVE NOT RECRUITING · NA
-
A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis
RECRUITING
-
A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy
RECRUITING
-
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
RECRUITING · Phase 1
-
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.